Original Source(s)
Related Content
FDA Expands Guselkumab Label in PsA
Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.
May 29, 2026
-
2 min
Cross-Linked HA Did Not Outperform Saline
Two single-injection cross-linked hyaluronic acid formulations showed no statistically significant advantage over saline for pain or functional outcomes through 24 weeks.
July 10, 2026
-
4 min